ly 311727 has been researched along with avapro in 1 studies
| Studies (ly 311727) | Trials (ly 311727) | Recent Studies (post-2010) (ly 311727) | Studies (avapro) | Trials (avapro) | Recent Studies (post-2010) (avapro) |
|---|---|---|---|---|---|
| 33 | 1 | 6 | 1,369 | 385 | 495 |
| Protein | Taxonomy | ly 311727 (IC50) | avapro (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.3067 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0099 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bandlow, N; Beck, S; Drexler, H; Grote, K; Kaszkin, M; Luchtefeld, M; Pfeilschifter, J; Schieffer, B; Tietge, UJ | 1 |
1 trial(s) available for ly 311727 and avapro
| Article | Year |
|---|---|
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Biphenyl Compounds; Cells, Cultured; Coronary Artery Disease; Enzyme Activation; Enzyme Inhibitors; Female; Group II Phospholipases A2; Humans; Hypertension; Indoles; Irbesartan; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles | 2007 |